The Russian anti-Covid-19 vaccine, Sputnik V, today marks two years of registration as the first of its kind globally to face the SarS-COV-2 coronavirus.
The drug, developed by the Gamaleya National Research Center for Epidemiology and Microbiology, was named after the first Soviet satellite and is registered in 71 countries, where more than 4 billion people live.
As detailed to the RT chain the executive director of the Russian Direct Investment Fund, Kirill Dmitriev, “in the two years since its registration, the Sputnik V vaccine has become the most exported drug in the history of Russia and has established itself as one of the tools safest and most effective ways to combat coronavirus infection around the world.
The specialist added that studies on Sputnik V are published in the main international peer-reviewed medical journals, among which stand out The Lancet, Nature, Vaccines, Cell Reports Medicine and others.
Dmitriev said that the immunizer not only helped protect people against the original strain of the pathogen and reduce the peak of the disease, but “its well-proven universal platform of human adenovirus vectors proved to be very effective in combating the new mutations, including the Delta and Ómicron strains”, he highlighted.
Likewise, he specified that the version of a single component of the vaccine, Sputnik Light, also developed at the initiative of the Fund, is used “successfully” in more than 30 countries.
“Sputnik Light, under the same active ingredient as Sputnik V, is a universal booster for other vaccines, providing greater protection against the Omicron variant and other mutations,” added Dmitriev.
He argued that “the pandemic became an important lesson for all of humanity, that when it comes to saving lives, unity and collective efforts are required.”
In this regard, he stated that only in this way is it possible to deal effectively with future threats, including those of an epidemiological nature.
Russia has five other vaccines against Covid-19: the adolescent version Sputnik M and the single-dose version Sputnik Light from the Gamaleya Center; the EpiVacCorona and EpiVacCorona-N vaccines, designed by the Vector Center for Virology and Biotechnologies; and CoviVac, produced by the Chumakov Center. (Latin Press)